Core Viewpoint - China Traditional Chinese Medicine (CTCM) reported a significant decline in revenue and a shift from profit to loss in its interim results for the six months ending June 30, 2025, primarily due to increased competition and changes in its business structure [1] Financial Performance - The company achieved a revenue of 7.463 billion yuan, representing a year-on-year decrease of 11% [1] - The loss attributable to shareholders was 108 million yuan, compared to a profit of 211 million yuan in the same period last year [1] - Basic loss per share was 2.14 cents [1] Business Strategy - The decline in revenue was attributed to a significant increase in the proportion of traditional Chinese medicine formula granules in the collective procurement business, alongside intensified market competition [1] - The company is actively promoting structural optimization in its business operations, focusing on the development of advantageous and local varieties of traditional Chinese medicinal materials while strategically reducing low-margin and high-risk businesses [1] - The traditional Chinese medicine health sector has paused certain homogenized and non-competitive product lines, contributing to the revenue decline [1]
中国中药(00570)发布中期业绩，股东应占亏损1.08亿元，同比盈转亏